Subject(s)
Internship and Residency , Personnel Staffing and Scheduling , Female , Humans , Male , Occupational Health , Social Problems , Workload , Time FactorsSubject(s)
Biomedical Research/economics , Child Welfare , National Institutes of Health (U.S.)/economics , Research Support as Topic/economics , Child , Child, Preschool , Hospital Departments/economics , Hospitals, Pediatric/economics , Humans , Pediatrics/economics , Research Support as Topic/trends , United StatesSubject(s)
Blood Donors/statistics & numerical data , Blood Safety/trends , Communicable Disease Control/trends , Communicable Diseases, Emerging/blood , Communicable Diseases, Emerging/epidemiology , Animals , Blood Donors/supply & distribution , Blood Safety/history , Blood Safety/methods , Blood Transfusion/history , Communicable Disease Control/methods , Communicable Diseases, Emerging/prevention & control , Communicable Diseases, Emerging/transmission , Congresses as Topic , History, 21st Century , Humans , National Heart, Lung, and Blood Institute (U.S.)/organization & administration , Transfusion Reaction , United States/epidemiologyABSTRACT
Efforts to enhance therapy for children and adults with sickle cell disease (SCD) have proven more challenging than might have been predicted from the fact that an understanding of the underlying pathogenesis antedated that of many other diseases for which good treatments presently exist. The multi-organ injury that occurs with SCD certainly contributes to this clinical reality. Research over decades indicates that the primary defect in hemoglobin that results in polymerization of the protein under low oxygen conditions and resultant cellular deformity of the red blood cell initiates a complex downstream pathogenesis associated with vascular injury and organ ischemia. Deciphering this in a manner that informs successful therapies that improve all target organs continues to challenge hematologists. The National Heart, Lung and Blood Institute (NHLBI) is dedicated to support research across the basic science, translational and clinical spectrum to achieve these clinical outcomes. The following provides a brief summary of the research strategies which NHLBI is presently supporting and will support in the future to enhance care and ultimately, to effect cure of this hemoglobin disease that causes such suffering to those who inherit this monogenic disease.
Subject(s)
Anemia, Sickle Cell/therapy , Biomedical Research/trends , Adult , Child , Humans , National Institutes of Health (U.S.) , United StatesABSTRACT
Over the past 8 years, the National Institutes of Health (NIH) budget appropriation has lost purchasing power, with erosion of the benefits of the doubling of the budget less than a decade ago. For the first time in 40 years, the NIH appropriation in fiscal year 2011 was 1% less than in the previous year. The National Heart, Lung, and Blood Institute (NHLBI) has been closely managing its funds to protect its core functions: support and conduct of research, and training of biomedical research scientists. Rigorous evaluations of funding mechanisms, management of clinical studies, set-aside programs and funding guidelines are designed to help the Institute, in consultation with its advisory council, to minimize the long-term impact of extreme resource limitations on the advance and conduct of science. This report describes some recent actions taken by the NHLBI to maximize support for investigator-initiated research, maintain a balanced portfolio, and provide as much support as possible for established and early-stage investigators.
Subject(s)
Biomedical Research/economics , National Heart, Lung, and Blood Institute (U.S.)/economics , National Heart, Lung, and Blood Institute (U.S.)/organization & administration , Research Support as Topic/organization & administration , Biomedical Research/trends , Budgets/trends , Guidelines as Topic , Humans , National Heart, Lung, and Blood Institute (U.S.)/trends , Research Support as Topic/trends , Small Business/economics , Small Business/trends , United StatesABSTRACT
Monogenic deficiency diseases provide unique opportunities to define the contributions of individual molecules to human physiology and to identify pathologies arising from their dysfunction. Here we describe a deficiency disease in two human siblings that presented with severe bleeding, frequent infections and osteopetrosis at an early age. These symptoms are consistent with but more severe than those reported for people with leukocyte adhesion deficiency III (LAD-III). Mechanistically, these symptoms arose from an inability to activate the integrins expressed on hematopoietic cells, including platelets and leukocytes. Immortalized lymphocyte cell lines isolated from the two individuals showed integrin activation defects. Several proteins previously implicated in integrin activation, including Ras-associated protein-1 (RAP1) and calcium and diacylglycerol-regulated guanine nucleotide exchange factor-1 (CALDAG-GEF1), were present and functional in these cell lines. The genetic basis for this disease was traced to a point mutation in the coding region of the KINDLIN3 (official gene symbol FERMT3) gene. When wild-type KINDLIN-3 was expressed in the immortalized lymphocytes, their integrins became responsive to activation signals. These results identify a genetic disease that severely compromises the health of the affected individuals and establish an essential role of KINDLIN-3 in integrin activation in humans. Furthermore, allogeneic bone marrow transplantation was shown to alleviate the symptoms of the disease.